Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients
Open Access
- 21 October 2022
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (12) , 2858-2867
Abstract
This study conducted a pairwise comparison of antihypertensive and metabolic effects of hydrochlorothiazide (HCTZ) and chlorthalidone (CTD) at 25 mg/day in the same individuals to address the clinical dilemma on preferred thiazide for hypertension (HTN) management. We included 15 African American (AA) and 35 European American (EA) patients with HTN treated with HCTZ and CTD as part of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR‐2 trials, respectively. Mean reduction in systolic/diastolic blood pressure (SBP/DBP) with HCTZ versus CTD was 8/5 versus 16/8 mmHg among EA patients (p < 1.0e−5 SBP, p = 0.002 DBP) and 11/8 versus 20/11 mmHg among AA patients (p = 0.03 SBP, p = 0.22 DBP). While CTD showed clinically meaningful benefit over HCTZ in two‐thirds of participants with respect to SBP reduction and half of EA patients with respect to DBP reduction, a majority of AA patients (53%) showed similar DBP reduction with both thiazides. Sixty percent of AA patients and 29% of EA patients attained blood pressure (BP) p = 0.0002) and AA patients (0.49, p = 0.043). While 31% of AA patients developed severe hypokalemia on CTD, <5% of others developed severe hypokalemia. Although 46% of AA patients on CTD required K+ supplementation, only 6%–11% of others required supplementation. Overall, in the majority of EA patients, CTD was superior to HCTZ, whereas among AA patients, it was superior in a minority, and was associated with significant potassium‐related risk, suggesting that guideline preferences for CTD over HCTZ are reasonable in EA patients but may be less reasonable in AA patients, particularly if the target is <140/90 mmHg.Keywords
Funding Information
- American Heart Association (20PRE35210065)
- Mayo Foundation for Medical Education and Research
- National Center for Advancing Translational Sciences (UL1 TR000135, UL1 TR000454, UL1 TR000064)
This publication has 34 references indexed in Scilit:
- Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan MedoxomilThe American Journal of Medicine, 2012
- Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and AtenololAmerican Journal of Hypertension, 2012
- Chlorthalidone Versus Hydrochlorothiazide as the Preferred DiureticHypertension, 2011
- Plasma Renin Activity Predicts Blood Pressure Responses to -Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for HypertensionAmerican Journal of Hypertension, 2010
- The Choice of Thiazide DiureticsHypertension, 2009
- Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studyAmerican Heart Journal, 2009
- Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood PressureHypertension, 2006
- Hydrochlorothiazide Versus ChlorthalidoneHypertension, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Effects of Aerobic Exercise in Normotensive AdultsSouthern Medical Journal, 1995